echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > ESMO directly hit Belzutifan, VHL-associated renal cell carcinoma ORR reached 64%

    ESMO directly hit Belzutifan, VHL-associated renal cell carcinoma ORR reached 64%

    • Last Update: 2022-09-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com


    The 2022 Annual Meeting of the European Society of Oncology (ESMO) was held



    Hipper-Lindau syndrome (VHL) is a rare autosomal dominant disorder manifesting as angioblastoma involving the cerebellum, spinal cord, kidneys, and retina




    background


    The transcription factor HIF-2α is a recognized carcinogenic driver whose activation in VHL disease is caused



    method


    Adult patients who are eligible (germ cell VHL mutation, non-metastatic RCC measurable lesion ≥1, RCC lesion without >3 cm requiring immediate surgery, previous systemic antineoplastic therapy, ECOG PS 0-1) are treated with belzutifan (120 mg once daily) until disease progression, intolerable toxicity occurs, or the patient withdraws consent



    Figure 1 Study design


    outcome


    As of 1 April 2022, 38/61 (62%) of patients were still receiving treatment, and the main reasons for discontinuation of treatment were patient selection (n=11,18%) and disease progression (n=6,10%)



    Figure 2 Remission in patients with RCC

    The incidence of grade 3 treatment-related adverse events (TRAEs) was 18% (n=11), with the most common being anemia (n=7,11%)
    .

    No level 4 or 5 TRAEs occur
    .

    conclusion

    In the case of a median follow-up period of 37.
    8 months, belzutifan showed good antitumor activity and controllable safety against VHL-associated RCCs
    .

    Reference Sources

    LR

    Reviewed: LR

    Execution: LR

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.